Commentary
The Biden administration is boosting biotech. Big time.
Thinking About China
Opinion
Biden’s New Biotech Order
China threat drives America into subsidizing its bioeconomy
A unit dedicated to the production of insulin pens at the factory of the U.S. pharmaceutical company Eli Lilly in Fegersheim, eastern France, on Oct. 12, 2015. Frederick Florin/AFP via Getty Images
Anders Corr
Author
Anders Corr has a bachelor's/master's in political science from Yale University (2001) and a doctorate in government from Harvard University (2008). He is a principal at Corr Analytics Inc. and publisher of the Journal of Political Risk, and has conducted extensive research in North America, Europe, and Asia. His latest books are “The Concentration of Power: Institutionalization, Hierarchy, and Hegemony” (2021) and “Great Powers, Grand Strategies: the New Game in the South China Sea" (2018).
